Invest Like the Best × Alex Karnal — the trillion-dollar public-health revolution
Patrick O'Shaughnessy's Apr 2026 episode with bio-investor Alex Karnal makes the case that GLP-1s, PCSK9 inhibitors, and peptides collectively represent the largest public-health inflection since antibiotics. Here's the thesis, the chapters that matter for peptide buyers, and every compound mentioned.
Why this episode matters
Alex Karnal is the founder of Braidwell and, per Patrick, "the most talented bio and healthcare investor I've ever met." He has spent 20 years in the industry and opens the episode by calling 2025 "the single most exciting year he's seen — the start of a once-in-a-lifetime, trillion-dollar revolution in public health."
For peptide buyers, two things make this episode worth your time over any other bio-investor conversation:
- Karnal names "Citizen Pharmacology and the Peptide Movement" as a standalone chapter — it is the first mainstream investor conversation to treat peptides as a category rather than a sub-story inside GLP-1.
- He frames the oral GLP-1 wave as "breaking every adoption record in pharma" — the quantitative backdrop for the Amazon / One Medical launch that landed the same week.
Source tweets: @patrick_oshag announcement ↗ · @Ashwinreads summary ↗
The through-line
Karnal's thesis, as we read it:
We already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them.
He illustrates with PCSK9: a population born with a natural mutation that doesn't produce the PCSK9 protein has an 88% lower lifetime cardiovascular risk. Pharma has had an approved PCSK9-inhibitor drug for years. Almost no one takes it — partly because high cholesterol is silent, partly because the health system makes preventive drugs punishingly hard to stay on.
The "trillion-dollar revolution" is not new molecules. It is the unlock between existing-medicines-that-work and the distribution systems-that-actually-get-them-to-people. Oral GLP-1s break the record because they close that gap. Peptides are the next category where the gap is about to close.
Chapter map (timestamps from the episode)
| Timestamp | Chapter | Relevance |
|---|---|---|
| 1:00 | The State of Modern Medicine | Frame for the whole episode |
| 5:00 | Designing the Modern Health Stack | Karnal's personal stack |
| 12:17 | The GLP-1 Inflection Point | Direct Pepwizard category |
| 19:18 | Biological Mechanisms of GLP-1 | Mechanism context |
| 30:36 | Overcoming Frictions in Healthcare | Distribution / telehealth |
| 34:19 | Cardiovascular Disease | PCSK9, statins |
| 44:04 | Addressing Alzheimer's | Adjacent |
| 47:04 | The Future of Cancer | Adjacent |
| 57:33 | Drug Discovery | AI + pharma |
| 1:05:25 | AI and Scientific Super Intelligence | Adjacent |
| 1:14:40 | Citizen Pharmacology and the Peptide Movement | Direct Pepwizard category |
| 1:18:13 | Background and Career Journey | Bio |
The two chapters marked bold are the ones to listen to if you're time-boxed on peptides specifically.
Compounds and frameworks mentioned
- Semaglutide / Wegovy / Ozempic — the wedge. Live prices.
- Tirzepatide / Mounjaro / Zepbound — the SURMOUNT-5 superior. Live prices.
- Retatrutide — the triple-agonist, currently Phase 3. Live prices.
- Orforglipron — the oral GLP-1 that's "breaking every adoption record." Live prices.
- PCSK9 inhibitors — Karnal's cardiovascular prevention case study (not a peptide).
- Citizen pharmacology — Karnal's framing for the growing gap between institutional pharma distribution and consumer-driven compound access, which Pepwizard exists inside of.
What we'd add as a peptide-site
Karnal's distribution-is-the-moat thesis is correct, and it explains why:
- Amazon entering GLP-1 at $149/month is an inflection, not an incremental price cut.
- The FDA's direction on peptide compounding matters more than any individual peptide's efficacy data.
- Vendors that solve distribution trust (COAs, verified shipping, consistent reconstitution guidance) win over vendors that only solve price.
We have a vendor-tier breakdown exactly for buyers trying to parse this landscape. And the Q2 2026 Peptide Index has the price-trend data Karnal's thesis implies.
Compounds below, with live prices
If the episode made you curious about any of these, prices are live from every tracked vendor.